Why EGFR Drugs Fail in Glioblastoma: A STAT3 Escape Route Takes Center Stage
A new review argues that glioblastoma evades EGFR-targeted therapies through compensatory STAT3 activation, positioning the EGFR–STAT3 axis as an adaptive ...
A new review argues that glioblastoma evades EGFR-targeted therapies through compensatory STAT3 activation, positioning the EGFR–STAT3 axis as an adaptive ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine